Back to Journals » Cancer Management and Research » Volume 12

LINC02381 Promoted Cell Viability and Migration via Targeting miR-133b in Cervical Cancer Cells

Authors Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J

Received 4 November 2019

Accepted for publication 19 April 2020

Published 26 May 2020 Volume 2020:12 Pages 3971—3979

DOI https://doi.org/10.2147/CMAR.S237285

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Xiaohua Chen, Zhuxiang Zhang, Yan Ma, Hongxin Su, Peng Xie, Juntao Ran

Department Of Radiation Therapy, First Hospital Of Lanzhou University, Lanzhou City, Gansu Province 730000, People’s Republic of China

Correspondence: Juntao Ran
Department Of Radiation Therapy, First Hospital Of Lanzhou University, No. 1 Donggang West Road, Chengguan District, Lanzhou City, Gansu Province 730000, People’s Republic of China
Tel +86 931-8356435
Email kyxfjedpjge1@163.com

Background: It has been proved that lncRNAs could function as CeRNA for miRNAs in tumor growth and metastasis for cervical cancer. This paper aims to identify the role of LINC02381 in cervical cancer cells.
Materials and Methods: RT-qPCR was utilized to measure the expression levels of LINC02381 in cervical cancer tissues and cells. MTT, colony formation assay, transwell assay, RT-qPCR, and Western blotting were performed to investigate the roles of LINC02381 in cervical cancer cells. RegRNA 2.0 was used to predict the miRNA-binding sites of LINC02381. Luciferase reporter assay and RT-qPCR were employed to confirm the sponging effect between miR-133b and LINC02381.
Results: This study showed that LINC02381 was up-regulated in cervical cancer cells and acted as an oncogene in the development of cervical cancer. LINC02381 promoted cell viability and metastasis via sponging miR-133b. Moreover, miR-133b could target its downstream mediator of RhoA and inhibit its expression.
Conclusion: Overall, our results indicated that LINC02381 functions as an oncogene in cervical cancer and could serve as a novel target for cervical cancer therapies in the future.

Keywords: LINC02381, miR-133b, RhoA, cervical cancer, cell viability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]